Flavoxate is a drug, indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate is not indicated for definitive treatment, but is compatible with drugs used for the treatment of urinary tract infections. It was approved for use in the United States in 1970 and continues to be used. Drug acts as a direct antagonist at muscarinic acetylcholine receptors in cholinergically innervated organs. Its anticholinergic-parasympatholytic action reduces the tonus of smooth muscle in the bladder, effectively reducing the number of required voids, facilitating increased volume per void. Common side effects are those of parasympathetic stimulation and include dryness of the mouth and eyes, decreased sweating, headache, visual blurring, constipation, urinary retention, impotence, tachycardia and palpitations, anxiety, restlessness and in some instances agitation and delusions.

ASC-J9, also known dimethylcurcumin, is an androgen receptor (AR) degradation enhancer, it suppresses AR function via selective interruption between androgen receptors (ARs) and its selective co-activators (ARA55 or ARA70). This drug was successfully passed phase II clinical trial for topical application to treat the facial acne. In addition, ASC-J9 participated in the preclinical experiments to suppress prostatitis by altering the autoimmune response induced by CD4 T cell recruitment. In combination with sorafenib was shown, that ASC-J9 suppressed the hepatocellular carcinoma (HCC) progression via altering the pSTAT3-CCL2/Bcl2 signals.

Fispemifene acts via estrogen receptors and has tissue-selective estrogenic and/or antiestrogenic effects – it has antagonist activity in breast tissue and acts as an estrogen agonist in bone. Due to its low estrogenicity in male rats, it might also be applicable for men. Fispemifene exhibits both antiestrogenic and anti-inflammatory action in the prostate. It could be considered as a new therapeutic option in the treatment and prevention of prostatic inflammation. Fispemifene had been in phase II clinical trials for the oral treatment of hypogonadism.

Verbenalin is an iridoid glycoside, and an alkaloid as well, found in Verbena officinalis. Verbenalin has demonstrated cardioprotection against experimental myocardial ischemic injury. It attenuated hypoxia-induced cytotoxicity significantly in H9c2 cells in a concentration-dependent manner. Treatment of H9c2 cells with Verbenalin blocked the reduction of expression of phospho-CREB and phospho-Akt in a hypoxic condition. Verbenalin can protect myocardial function in rats during myocardial I/R injury, suggesting the therapeutic potential of Verbenalin against myocardial I/R injury. Verbenalin also exhibited significant anti-HCV entry and anti-infectivity activities.

Norfloxacin is an antibacterial agent, It inhibits inhibits DNA synthesis by inhibiting DNA gyrase enzyme. Norfloxacin was approved in 1986 for treatment of urinary tract infections, gynecological infections, prostatitis, gonorhhea and bladder infections. In ophtalmology, norfloxacin is used for treatment of conjunctivitus.

Carfecillin is a phenyl ester of the side-chain carboxyl group of carbenicillin, beta-lactam antibiotic, acting as a prodrug. Upon oral administration, is broken down in the intestinal mucosa to the active antibacterial. It is used for urinary tract infections.

Calcium glycerophosphate (brand name Prelief) is a relatively new mineral complex primarily used to neutralize acidic foods when consumed and to protect teeth. Prelief is AkPharma's brand name has a number of important uses. As a palliative in interstitial cystitis, prostatitis, overactive bladder. As a symptoms reducer in irritable bowel syndrome. Through a mechanism not fully elucidated, but it appears to reduce cellular inflammation in the urinary bladder.

Tosufloxacin is a fluoroquinolone antibacterial agent. Tosufloxacin is an inhibitor of bacterial DNA gyrase and topoisomerase IV. Tosufloxacin is indicated for the treatment of various infections such as skin, respiratory, urinary, gynecologic, ophthalmologic, otolaryngologic, dental infections. Fluoroquinolones including tosufloxacin have a potential risk of inducing cartilage and joint toxicity in children. It is also associated with severe thrombocytopenia and nephritis, and hepatotoxicity.

Geocillin (carbenicillin indanyl sodium) is indicated in the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria. Geocillin is also indicated in the treatment of prostatitis due to susceptible strains of the following organisms: Escherichia coli Enterococcus (S. faecalis) Proteus mirabilis Enterobacter sp. Geocillin is acid stable, and rapidly absorbed from the small intestine following oral administration. It provides relatively low plasma concentrations of antibiotic and is primarily excreted in the urine. The antibacterial activity of Geocillin is due to its rapid conversion to carbenicillin by hydrolysis after absorption. Carbenicillin binds to penicillin-binding protein from corresponding bacteria. In April 2008, Pfizer has decided to discontinue the manufacturing of Geocillin (carbenicillin indanyl sodium). There are no other currently FDA approved manufacturers for carbenicillin tablets.

Flavoxate is a drug, indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate is not indicated for definitive treatment, but is compatible with drugs used for the treatment of urinary tract infections. It was approved for use in the United States in 1970 and continues to be used. Drug acts as a direct antagonist at muscarinic acetylcholine receptors in cholinergically innervated organs. Its anticholinergic-parasympatholytic action reduces the tonus of smooth muscle in the bladder, effectively reducing the number of required voids, facilitating increased volume per void. Common side effects are those of parasympathetic stimulation and include dryness of the mouth and eyes, decreased sweating, headache, visual blurring, constipation, urinary retention, impotence, tachycardia and palpitations, anxiety, restlessness and in some instances agitation and delusions.